Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization
暂无分享,去创建一个
[1] B. Graham. Clinical trials of HIV vaccines. , 2002, Annual review of medicine.
[2] A. Dawid. Causal Inference without Counterfactuals , 2000 .
[3] D. Rubin. [On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9.] Comment: Neyman (1923) and Causal Inference in Experiments and Observational Studies , 1990 .
[4] James M. Robins,et al. Causal Inference Without Counterfactuals: Comment , 2000 .
[5] M. Halloran,et al. Causal Inference in Infectious Diseases , 1995, Epidemiology.
[6] Niels Keiding,et al. Statistical Models Based on Counting Processes , 1993 .
[7] T. VanderWeele. Simple relations between principal stratification and direct and indirect effects , 2008 .
[8] D. Mehrotra,et al. Eliciting a Counterfactual Sensitivity Parameter , 2007 .
[9] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[10] Winfried Stute,et al. The Central Limit Theorem Under Random Censorship , 1995 .
[11] D. Rubin. Comment on "Causal inference without counterfactuals," by Dawid AP , 2000 .
[12] J. Robins,et al. Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models , 1999 .
[13] J. Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .
[14] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[15] D. Rubin,et al. Principal Stratification in Causal Inference , 2002, Biometrics.
[16] Roderick J. A. Little,et al. Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models: Comment , 1999 .
[17] Donald B. Rubin,et al. Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .
[18] M. Hudgens,et al. Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials , 2003, Biometrics.
[19] A A Tsiatis,et al. Causal Inference on the Difference of the Restricted Mean Lifetime Between Two Groups , 2001, Biometrics.
[20] G. Nabel. Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.
[21] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[22] P. Rosenbaum. The Consequences of Adjustment for a Concomitant Variable that Has Been Affected by the Treatment , 1984 .
[23] Andrea Rotnitzky,et al. Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials , 2006, Biometrics.
[24] Michael G Hudgens,et al. On the analysis of viral load endpoints in HIV vaccine trials , 2003, Statistics in medicine.
[25] James M. Robins,et al. An analytic method for randomized trials with informative censoring: Part II , 1995, Lifetime data analysis.
[26] Michael G Hudgens,et al. Causal Vaccine Effects on Binary Postinfection Outcomes , 2006, Journal of the American Statistical Association.